Lineus Medical Completes Financial Restructuring with KMF Investments- Launching a New Era for SafeBreak

FAYETTEVILLE, Ark. - PrZen -- Lineus Medical, a leader in vascular access innovation and maker of SafeBreak® Vascular, the first breakaway device for IV lines, announced completion of a strategic recapitalization with KMF Investments. Finalized at the start of 2026, the transaction establishes KMF as a stable financial backer of Lineus Medical, providing the organizational and commercial foundation for the company as it closes out a landmark first quarter and sets its sights on accelerated growth through the remainder of the year.

Lineus Medical retains its name, leadership, and mission-driven focus and deepens its commitment to remove the pains associated with IV lines for patients, nurses, and healthcare systems worldwide. The recapitalization in conjunction with the Breakaway Impact Registry, a real time registry capturing data that measure the health-economic impact of SafeBreak for each hospital, has accelerated trialing and adoption of SafeBreak Vascular throughout the United States.

"Starting the year as a company with new sales momentum in motion is a strong signal of what's ahead," said Jonathon Fite, Managing Partner and Co-Founder of KMF Investments. "The Breakaway Impact Registry gives our commercial team a clear, outcomes-driven framework for showing hospitals exactly what SafeBreak Vascular can do for their patients and their bottom line. We have never been better positioned to scale."

"This merger is the result of a shared belief that patients deserve SafeBreak Vascular on every IV line they receive," said Arvind Mallik, Managing Partner and Co-Founder of KMF Investments. "KMF and Lineus Medical have been aligned on that mission from the start. Now, we have the structure, the strategy, and the momentum to make it happen."

"What excites me most about where Lineus Medical stands today is the sales team we have built," said Vance Clement, Chief Executive Officer of Lineus Medical. "We now have the right people in place with the experience, people skills, and drive to scale SafeBreak Vascular across health systems of every size. This recapitalization gives us the financial resources to fully activate that team, and I am confident in our ability to grow."

"The commercial progress we have made through Q1 is a direct reflection of a strategy that is working," said Larry Hayes Chief Commercial Officer of Lineus Medical. "We are adding accounts, expanding our clinical footprint, and building a data set through the Breakaway Impact Registry that tells a compelling story grounded in both clinical and economic value. That combination is what moves hospitals from interest to adoption."

SafeBreak® Vascular is a breakaway device for IV lines that separates when a damaging force is applied to the IV line to remove the damaging force and protect the patient's IV line. When separation occurs, valves on both ends of the device close to prevent medication spills from the pump and blood loss from the patient. SafeBreak has been shown to reduce mechanical IV complications in a range of 44% to 91%.¹ The device is FDA-cleared for use across all vascular access lines, CE Mark certified for use across the European Union, and is distributed across markets spanning more than three continents.

About Lineus Medical

Lineus Medical is the developer of SafeBreak® Vascular, a breakaway technology proven to reduce IV restarts and IV complications.¹ Our mission is to remove the pains associated with medical lines. More information about Lineus Medical can be found at www.lineusmed.com. Follow Lineus Medical on LinkedIn, Facebook, and Instagram.

References:

1.      1.  Data on File

MKG 0440 Rev 00